Next-Generation CAR-T : The Race to Win the Future of Immuno-Oncology

Novel gene editing technologies and lean manufacturing processes could unleash the potential of CAR-T in both blood and solid tumors, but with hundreds of potential drugs in development, who wins?

Source: MSKCC

Fundamentally, the advent of CAR-T signaled a paradigm shift in drug development from molecules and biologics to living cells.

While biochemists have spent thousands of hours optimizing small molecule chemotherapies over the last century, today’s molecular biologists are meticulously tweaking the genetic code of living immune cells to maximize their therapeutic potential and miminize their toxicity in the fight against cancer.

In this analysis, I cover:

• A brief overview on the history of CAR-T.
• The current FDA-approved therapies on the market and the drug candidates not far behind.
• The technologies that both biotech startups and big pharma are using to build next-generation adoptive cell therapies.
• Predictions for which assets will be valuable in the next couple years.
• Distinct market strategies that companies are betting on based on their pipelines, capex spend, and clinical trial results.